Scott B. Ullem sold $1.1M of EW
CVP, Chief Financial Officer at Edwards Lifesciences Corp. 13,000 shares at an average of $84.92, traded Mar 11, 2026, filed Mar 11, 2026.
Score components
- +22RoleCFO
- +25Trade size$1.1M at market
- +5Share of holdings soldSold 25% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -8.5%, 3m +1.0%, 6m +1.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001225208-26-003539, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 11, 2026 | MOption exercise Common Stock10b5-1 | +13,000 | $59.26 | $770k | 52,699 | Mar 11, 2026 |
| Mar 11, 2026 | SOpen-market sale Common Stock10b5-1 | -5,099 | $84.46 | $431k | 47,600 | Mar 11, 2026 |
| Mar 11, 2026 | SOpen-market sale Common Stock10b5-1 | -7,901 | $85.21 | $673k | 39,699 | Mar 11, 2026 |
| Mar 11, 2026 | MOption exercise Employee Stock Option (Right to Acquire)derivative10b5-1 | -13,000 | $0.00 | $0 | 26,000 | Mar 11, 2026 |
Related signals
Other insiders at Edwards Lifesciences Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Edwards Lifesciences Corp | Daniel J. Lippis CVP, TAVR | $53k 619 shares | -2% | |
| 2Weak | Edwards Lifesciences Corp | Daniel J. Lippis CVP, TAVR | $54k 619 shares | -2% | |
| 37Weak | Edwards Lifesciences Corp | Andrew M. Dahl SVP, Corporate Controller | $50k 544 shares | -4% | |
| 48Moderate | Edwards Lifesciences Corp | Annette Bruls CVP, EMEACLA | $238k 2,644 shares | -13% | |
| 50Moderate | Edwards Lifesciences Corp | Daveen Chopra CVP, TMTT, Surgical & IHFM | $2.9M 31,800 shares | -42% | |
| 40Moderate | Edwards Lifesciences Corp | Wayne Markowitz CVP, JAPAC | $113k 1,240 shares | -6% | |
| 0Weak | Edwards Lifesciences Corp | Daniel J. Lippis CVP, TAVR | $57k 619 shares | -2% | |
| 30Weak | Edwards Lifesciences Corp | Wayne Markowitz CVP, JAPAC | $13k 146 shares | -1% | |
| 47Moderate | Edwards Lifesciences Corp | Wayne Markowitz CVP, JAPAC | $819k 9,628 shares | -31% | |
| 51Moderate | Edwards Lifesciences Corp | Bernard J Zovighian CEO | $245k 2,921 shares | -25% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.